Skip to content
DraconiticResearch
Search Sources API
193,349 studies31 sourcesUpdated 31 min ago
Peer-reviewedCC BY-NC-NDNeoplasia (New York, N.Y.)

Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.

  • Qiaoyan Qu1
  • Jintan Xiao2
  • Bingjian Zhao3
  • Peng Gu4
4 affiliations
  1. 1Department of Gastroenterology, Qingdao Municipal Hospital, No. 2, Chaocheng Road, Shinan District, Qingdao, Shandong, 266000, China. Electronic address: [email protected].
  2. 2Department of Emergency, Qingdao Municipal Hospital, No. 2, Chaocheng Road, Shinan District, Qingdao, Shandong, 266000, China. Electronic address: [email protected].
  3. 3Department of Gastroenterology, Qingdao Municipal Hospital, No. 2, Chaocheng Road, Shinan District, Qingdao, Shandong, 266000, China. Electronic address: [email protected].
  4. 4Department of Gastroenterology, Qingdao Municipal Hospital, No. 2, Chaocheng Road, Shinan District, Qingdao, Shandong, 266000, China. Electronic address: [email protected].
Read full textPDFDOICite

Abstract

CAR-T therapy yields remarkable clinical efficacy against hematological malignancies, yet its translation to solid tumors, particularly gastrointestinal cancers, is impeded by multiple bottlenecks including antigen heterogeneity, immunosuppressive tumor microenvironments and metabolic inhibition. This review systematically summarizes coping strategies for these barriers. Claudin-18.2, B7-H3 and c-Met represent attractive therapeutic targets eliciting tumor-specific cytotoxicity in gastric, colorectal and esophageal cancers. Structural modifications such as dual-targeted CARs, cytokine-expressing constructs and logic-gated receptors improve antigen specificity and mitigate off-tumor toxicity. Combination regimens with radiotherapy, immune checkpoint inhibitors and TME-modulating agents synergistically boost CAR-T infiltration, persistence and effector activity. Unresolved hurdles still involve antigen loss, production scalability and inconsistent clinical responses, which may be tackled by γδT-based platforms, synthetic biology and universal CAR designs. Adopting a challenge-solution paradigm, this review integrates cutting-edge clinical data to objectively dissect CAR-T progress in digestive tract malignancies and proposes a systematic optimization roadmap for future translational development.

Related

  1. Innovations and emerging trends in adoptive cell therapies for solid tumors: engineering strategies and clinical translation
    Peng Huang, WenLin Wu, Yu Min +5
    Experimental Hematology & OncologyPeer-reviewedCC BYFull textOncologyDOAJ
  2. Immunogenicity and vaccine effectiveness of COVID-19 vaccines in people on immunosuppressive therapies
    E. Stadler, S. R. Khan, K. M. Elias +10
    medRxivPreprintCC BYFull textInfectious diseasemedRxiv
  3. HER2-Low Breast Cancer: A Review of Epidemiology, Diagnostic Challenges, Targeted Therapies, and Clinical Outcomes
    Maedeh Mirasheh, Zahra Shahabinia, Mai Abdel Haleem A. Abusalah +4
    Journal of clinical medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Editorial: Translational strategies for chronic lung diseases: emerging therapies and precision medicine
    Poonam Arora, Lalit Mohan Nainwal
    Frontiers in PharmacologyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyCrossref
  5. Research Progress on Targeted Therapies for Pemphigus Vulgaris and Bullous Pemphigoid: Mechanisms, Opportunities and Challenges
    Wang-Fei Mo, Ya-Gang Zuo
    International journal of molecular sciencesPeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{qu2026engineering,
  title = {{Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.}},
  author = {Qiaoyan Qu and Jintan Xiao and Bingjian Zhao and Peng Gu},
  journal = {Neoplasia (New York, N.Y.)},
  year = {2026},
  month = oct,
  doi = {10.1016/j.neo.2026.101375},
  url = {https://europepmc.org/article/MED/42849114},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Engineering CAR-T cell therapies for digestive tract cancer: advances, challenges, and strategies to overcome tumor heterogeneity and immunosuppressive barriers.
AU  - Qiaoyan Qu
AU  - Jintan Xiao
AU  - Bingjian Zhao
AU  - Peng Gu
PY  - 2026
DA  - 2026/10/08
JO  - Neoplasia (New York, N.Y.)
DO  - 10.1016/j.neo.2026.101375
UR  - https://europepmc.org/article/MED/42849114
AB  - CAR-T therapy yields remarkable clinical efficacy against hematological malignancies, yet its translation to solid tumors, particularly gastrointestinal cancers, is impeded by multiple bottlenecks including antigen heterogeneity, immunosuppressive tumor microenvironments and metabolic inhibition. This review systematically summarizes coping strategies for these barriers. Claudin-18.2, B7-H3 and c-Met represent attractive therapeutic targets eliciting tumor-specific cytotoxicity in gastric, colorectal and esophageal cancers. Structural modifications such as dual-targeted CARs, cytokine-expressing constructs and logic-gated receptors improve antigen specificity and mitigate off-tumor toxicity. Combination regimens with radiotherapy, immune checkpoint inhibitors and TME-modulating agents synergistically boost CAR-T infiltration, persistence and effector activity. Unresolved hurdles still involve antigen loss, production scalability and inconsistent clinical responses, which may be tackled by γδT-based platforms, synthetic biology and universal CAR designs. Adopting a challenge-solution paradigm, this review integrates cutting-edge clinical data to objectively dissect CAR-T progress in digestive tract malignancies and proposes a systematic optimization roadmap for future translational development.
SN  - 1522-8002
SN  - 1476-5586
ER  -